SurVaxM® · Investigational Immunotherapy
New options for glioblastoma, engineered from the body’s own defenses.
MimiVax is a clinical-stage immunotherapy company. For 15 years we’ve worked bench to bedside on SurVaxM, a survivin-targeting vaccine designed for more life — tested first in glioblastoma, built for more.
SurVaxM is an investigational product. It has not been approved by the FDA. Information on this site is intended for healthcare professionals, researchers and industry partners.
Why SurVaxM is different
Not another approach to GBM. A different target entirely.
Most prior glioblastoma therapies were adapted from other cancers. SurVaxM was engineered for GBM from the start — and the mechanism itself is what makes it novel.
A genuinely novel structure
SurVaxM’s molecular design is distinct from prior GBM immunotherapies — engineered against the tumor, not repurposed from elsewhere.
The body’s own defenses
SurVaxM trains the immune system to recognize survivin, a protein overexpressed across GBM cells, turning natural defenses against the tumor.
Outpatient, well tolerated
Administered by subcutaneous injection in outpatient clinics.
One platform, built for more than GBM
Survivin is expressed across roughly 90% of cancers.
GBM is where the SurVaxM evidence is deepest today. The same platform is already being explored well beyond it.
- Active · Not recruiting Newly diagnosed glioblastoma (GBM)
- Completed Multiple myeloma
- Active · Recruiting Neuroendocrine tumors
- Paused · Reopens Q4 2026 Pediatric brain tumors
- In development Autoimmune disease (myasthenia gravis)
- Opening Q4 2026 Cancer prevention in high-risk smokers
Leadership & board
Built by the people who discovered and developed the vaccine.
MimiVax was founded by neuro-oncology clinicians who saw the need firsthand and took SurVaxM from the lab to the clinic themselves.
Michael J. Ciesielski, PhD
Robert A. Fenstermaker, MD
Danielle M. Casucci
Scott E. Friedman
Full bios for the executive team and board are on the Leadership & Board page.
For pharma & strategic partners
Be part of what comes after glioblastoma.
SurVaxM is a platform, not a single asset — validated first in the cancer with the fewest options, built to extend well beyond it. We welcome the conversation with partners who want to be part of something this exciting.